Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Martin Prazny"'
Autor:
Martin Prázný, Lyudmila Suplotova, Janusz Gumprecht, Zdravko Kamenov, Tibor Fülöp, Alexey Medvedchikov, Doron Rosenzweig, Milos Aleksandric
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-17 (2022)
Abstract Background Guidelines from 2016 onwards recommend early use of SGLT2i or GLP-1 RA for patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), to reduce CV events and mortality. Many eligible patients are not treated accordingly
Externí odkaz:
https://doaj.org/article/df7c4cf2f24543638cbd7bffdc452ab4
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
Abstract Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of C
Externí odkaz:
https://doaj.org/article/0dafb8b6594847eebbfd1bdddfd35c76
Autor:
Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč, Kārlis Trušinskis
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-9 (2019)
Abstract EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of e
Externí odkaz:
https://doaj.org/article/8d398bf5b3cb4286a35496a80a088901
Autor:
Guntram Schernthaner, Heinz Drexel, Evgeny Moshkovich, Birute Zilaitiene, Emil Martinka, Leszek Czupryniak, Tamás Várkonyi, Andrej Janež, Kristine Ducena, Katarina Lalić, Tsvetalina Tankova, Martin Prázný, Lea Smirčić Duvnjak, Olga Sukhareva, Harald Sourij
Publikováno v:
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-13 (2019)
Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively manda
Externí odkaz:
https://doaj.org/article/0272f69452424381adfcfdd3590cbea1
Autor:
Guntram Schernthaner, Roger Lehmann, Martin Prázný, Leszek Czupryniak, Kristine Ducena, Peter Fasching, Andrej Janež, Avraham Karasik, Peter Kempler, Emil Martinka, Marina V. Shestakova, Lea Smirčić Duvnjak, Tsvetalina Tankova
Publikováno v:
Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-12 (2017)
Abstract Aims These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent
Externí odkaz:
https://doaj.org/article/a98d192fce5b47699289f36bd5e7e85e
Autor:
LUCIE RADOVNICKÁ, ANETA HÁSKOVÁ, QUOC DAT DO, EVA HOROVA, VENDULA NAVRÁTILOVÁ, ONDREJ MIKES, DAVID CIHLÁR, CHRISTOPHER PARKIN, GEORGE GRUNBERGER, MARTIN PRAZNY, JAN SOUPAL
Publikováno v:
Diabetes. 71
We investigated the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) on change in A1C. CORRIDA LIFE was a 12 month, real-world, non-randomized trial that assessed the impact
Autor:
Edward B. Jude, Maciej T. Malecki, Ricardo Gomez Huelgas, Martin Prazny, Frank Snoek, Tsvetalina Tankova, Dario Giugliano, Kamlesh Khunti
Publikováno v:
Jude, E B, Malecki, M T, Gomez Huelgas, R, Prazny, M, Snoek, F, Tankova, T, Giugliano, D & Khunti, K 2022, ' Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes ', Diabetes Therapy, vol. 13, no. 4, pp. 619-634 . https://doi.org/10.1007/s13300-022-01222-2
Given the progressive nature of type 2 diabetes (T2D), most individuals with the disease will ultimately undergo treatment intensification. This usually involves the stepwise addition of a new glucose-lowering agent or switching to a more complex ins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6564ba65fa23e28edf3eba0b37a5094f
https://ruj.uj.edu.pl/xmlui/handle/item/290096
https://ruj.uj.edu.pl/xmlui/handle/item/290096
Autor:
Emil Martinka, Nebojsa Lalic, Andrej Janež, Lea Smircic-Duvnjak, Martin Prazny, Tsvetalina Tankova, Asimina Mitrakou, Adam G. Tabak, Leszek Czupryniak, Cristian Guja
Publikováno v:
Diabetes Therapy
Here, we review insulin management options and strategies in nonpregnant adult patients with type 1 diabetes mellitus (T1DM). Most patients with T1DM should follow a regimen of multiple daily injections of basal/bolus insulin, but those not meeting i
Autor:
Juris J. Meier, Cristian Guja, Julio Rosenstock, Lawrence Blonde, Robert Lubwama, Francesco Giorgino, Martin Prazny, Elisabeth Souhami, Amar Ali
Publikováno v:
Diabetes. 69
iGlarLixi, the once-daily fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, has been shown to robustly improve glycemic control in adults with T2D. To assess the effects of iGlarLixi with SGLT2i in T2D, we conducted subgroup anal
Publikováno v:
Diabetes. 69
Endothelial activation accelerated by oxidative stress (OxS) is believed to be the major step in development of diabetes angiopathy. The aim of this follow-up study was to measure microvascular reactivity (MVR) and markers of OxS. Our study involved